Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
NCT07244263Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Countries
- 8
01
Overview
A Phase 2 trial of zasocitinib in hidradenitis suppurativa (HS), sponsored by Takeda. Started Jan 2026; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07244263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244263.